IN2014CN03111A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN03111A IN2014CN03111A IN3111CHN2014A IN2014CN03111A IN 2014CN03111 A IN2014CN03111 A IN 2014CN03111A IN 3111CHN2014 A IN3111CHN2014 A IN 3111CHN2014A IN 2014CN03111 A IN2014CN03111 A IN 2014CN03111A
- Authority
- IN
- India
- Prior art keywords
- enantiomers
- fatty acids
- well
- methods
- hydroxy
- Prior art date
Links
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 3
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 3
- 229930195729 fatty acid Natural products 0.000 abstract 3
- 239000000194 fatty acid Substances 0.000 abstract 3
- 150000004665 fatty acids Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/487—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification
- C07C51/493—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification whereby carboxylic acid esters are formed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201131622A ES2401629B1 (es) | 2011-10-07 | 2011-10-07 | Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos. |
| US201261610762P | 2012-03-14 | 2012-03-14 | |
| PCT/ES2012/070697 WO2013050644A1 (es) | 2011-10-07 | 2012-10-08 | Enantiómeros de 2-hidroxiderivados de ácidos grasos |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN03111A true IN2014CN03111A (es) | 2015-07-03 |
Family
ID=48043212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3111CHN2014 IN2014CN03111A (es) | 2011-10-07 | 2012-10-08 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9359281B2 (es) |
| EP (2) | EP3287437B1 (es) |
| JP (1) | JP2014530806A (es) |
| CN (1) | CN104321300A (es) |
| DK (1) | DK2774910T3 (es) |
| ES (3) | ES2401629B1 (es) |
| HU (1) | HUE035430T2 (es) |
| IN (1) | IN2014CN03111A (es) |
| PL (1) | PL2774910T3 (es) |
| PT (1) | PT2774910T (es) |
| RU (2) | RU2637937C2 (es) |
| WO (1) | WO2013050644A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2345241B1 (es) * | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| US10047036B2 (en) * | 2014-10-21 | 2018-08-14 | Universitat De Les Illes Balears | Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases |
| ES2955524T3 (es) * | 2017-05-16 | 2023-12-04 | Ability Pharmaceuticals S A | Una combinación farmacéutica para el tratamiento de un cáncer |
| US11771672B2 (en) | 2017-11-16 | 2023-10-03 | The Research Foundation For The State University Of New York | Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies |
| KR20220132552A (ko) * | 2020-01-29 | 2022-09-30 | 유니버시다드 데 레스 일레스 발레아르스 | 알파-히드록실화 지방산의 대사산물, 이의 의학적 용도 및 바이오마커로서의 용도 |
| ES2846824B2 (es) * | 2020-01-29 | 2022-01-19 | Univ Illes Balears | Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos |
| ES2911474B2 (es) * | 2020-11-17 | 2023-02-06 | Univ Illes Balears | Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores |
| JP2023514036A (ja) * | 2020-02-10 | 2023-04-05 | アビリティ ファーマシューティカルズ エス．エル． | がんの治療のための薬学的組み合わせ |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2235541C2 (ru) * | 1994-10-04 | 2004-09-10 | Эмори Юниверсити | Лечение атеросклероза и других сердечно-сосудистых и воспалительных заболеваний |
| AUPR547601A0 (en) * | 2001-06-05 | 2001-06-28 | Carcraft Qld Pty Ltd | Tab with writing surface |
| ES2186576B1 (es) * | 2001-10-11 | 2004-09-16 | Universitat De Les Illes Balears | Acido 2-hidroxioleico para utilizar como medicamento. |
| ES2342997B1 (es) | 2008-12-09 | 2011-06-06 | Universitat De Les Illes Balears | Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento. |
| ES2345241B1 (es) * | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
-
2011
- 2011-10-07 ES ES201131622A patent/ES2401629B1/es active Active
-
2012
- 2012-10-08 ES ES17191078T patent/ES2773784T3/es active Active
- 2012-10-08 JP JP2014533953A patent/JP2014530806A/ja active Pending
- 2012-10-08 ES ES12838506.9T patent/ES2653675T3/es active Active
- 2012-10-08 WO PCT/ES2012/070697 patent/WO2013050644A1/es active Application Filing
- 2012-10-08 DK DK12838506.9T patent/DK2774910T3/en active
- 2012-10-08 PL PL12838506T patent/PL2774910T3/pl unknown
- 2012-10-08 EP EP17191078.9A patent/EP3287437B1/en active Active
- 2012-10-08 HU HUE12838506A patent/HUE035430T2/en unknown
- 2012-10-08 RU RU2014118123A patent/RU2637937C2/ru not_active Application Discontinuation
- 2012-10-08 IN IN3111CHN2014 patent/IN2014CN03111A/en unknown
- 2012-10-08 CN CN201280060748.XA patent/CN104321300A/zh active Pending
- 2012-10-08 US US14/349,962 patent/US9359281B2/en active Active
- 2012-10-08 PT PT128385069T patent/PT2774910T/pt unknown
- 2012-10-08 EP EP12838506.9A patent/EP2774910B1/en active Active
- 2012-10-08 RU RU2017141446A patent/RU2687967C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3287437B1 (en) | 2019-12-11 |
| PL2774910T3 (pl) | 2018-03-30 |
| RU2017141446A (ru) | 2019-02-13 |
| CN104321300A (zh) | 2015-01-28 |
| RU2014118123A (ru) | 2015-11-20 |
| HUE035430T2 (en) | 2018-05-02 |
| EP2774910A4 (en) | 2015-02-25 |
| RU2017141446A3 (es) | 2019-02-13 |
| EP3287437A1 (en) | 2018-02-28 |
| US9359281B2 (en) | 2016-06-07 |
| RU2637937C2 (ru) | 2017-12-08 |
| ES2401629B1 (es) | 2014-03-04 |
| ES2401629A1 (es) | 2013-04-23 |
| JP2014530806A (ja) | 2014-11-20 |
| WO2013050644A1 (es) | 2013-04-11 |
| PT2774910T (pt) | 2018-01-03 |
| DK2774910T3 (en) | 2018-01-08 |
| EP2774910A1 (en) | 2014-09-10 |
| RU2687967C2 (ru) | 2019-05-17 |
| EP2774910B1 (en) | 2017-09-27 |
| ES2773784T3 (es) | 2020-07-14 |
| ES2653675T3 (es) | 2018-02-08 |
| US20140288176A1 (en) | 2014-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN03111A (es) | ||
| AU2018260825A1 (en) | Compositions and Methods for Lowering Levels of High-Sensitivity (hs-CRP) in a Subject | |
| UA113186C2 (xx) | Макроциклічні інгібітори lrrk2 кінази | |
| BRPI0909040B8 (pt) | derivados de azetidina e ciclobutano, seus usos, e composição | |
| WO2014085830A3 (en) | Screening assays for therapeutics for parkinson's disease | |
| UA109459C2 (xx) | ПОХІДНІ 5,6-ДИГІДРОІМІДАЗО[1,2-a]ПІРАЗИН-8-ІЛАМІНУ, ПРИДАТНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE) | |
| MX2011008448A (es) | Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia. | |
| TR201909777T4 (tr) | Sübsti̇tüe ki̇nazoli̇nonlara yöneli̇k oral çabuk salimli formülasyonlar | |
| AR084433A1 (es) | Inhibidores de la faah y composiciones farmaceuticas que los contienen | |
| EP4338805A3 (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| BR112014021634A8 (pt) | inibidores de serina/treonina quinase,composições que os compreendem, seus usos e seus processos de preparação, e método de inibir a atividade da proteína quinase erk em uma célula | |
| TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
| HK1136283A1 (en) | Compounds for the prevention and treatment of cardiovascular diseases | |
| PH12013502369A1 (en) | Diazacarbazoles and methods of use | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| UY32682A (es) | "derivados de 1h-imidazo-[4,5-c]-quinolinona" | |
| UY32691A (es) | Compuestos de 1h-imidazo-[4,5-c]-quinolinona | |
| GT201200252A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| IN2015DN01151A (es) | ||
| IN2012DN05186A (es) | ||
| MX2012006822A (es) | 1,7-diazacarbazoles y metodos de uso. | |
| EP2257161A4 (en) | AHCY HYDROLASE INHIBITORS FOR THE TREATMENT OF HYPER-HOMOCYSEINEMIA | |
| IN2014CN03854A (es) | ||
| SV2009003286A (es) | Sal de potasio cristalina de analogos de lipoxina a4 | |
| BR112013026680A2 (pt) | composto, método de tratamento de uma doença inflamatória e composição farmacêutica |